Cloning of candidate genes involved in the Beckwith-Wiedemann syndrome and childhood tumors

✍ Scribed by Alders, M.; Bliek, J.; Redeker, B.; Ryan, A.; Feinberg, A.; Westerveld, A.; Little, P.; Mannens, M.

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 229 KB
• Volume: 27
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199611)27:5<495::aid-mpo18>3.0.co;2-9

✦ Synopsis

INAUGURAL DR. ClULlO 1. D'ANGIO AWARD

of adults who have been both cured of their tumor and

In 1940, the diagnosis of Wilms' tumor was associated with the same poor prognosis as that of other forms of childhood cancer. The addition of radiation therapy, and then chemotherapy to the management plan for these children improved their prognosis. However, the more aggressive therapy caused late complications which were of concern to the pioneers of pediatric oncology.

Giulio J. D' Angio, M.D., has focused his professional career on recognizing the need for an appreciation of the balance that must be achieved between successful therapy and reduction of late morbidity from treatment. The National Wilms' Tumor Study Group (NWTSG), which he founded, has completed four studies which had as their goals increasing the survival rate of children with Wilms' tumor and improving the quality of life of the successfully treated children. No one has been more thoughtful or energetic than Dr. D'Angio in the pursuit of these goals. The results of the NWTSG therapeutic trials have formed the basis for the treatment of children with Wilms' tumor on all continents, treatment which will lead to a population spared much of the morbidity, thought, prior to the first National Wilms' Tumor Study in 1969, to be an unavoidable cost of successful treatment.

Throughout his career, Dr. D'Angio has fostered the development of young investigators, recognizing both the importance of these for the continued evolution of pediatric oncology, and their "endangered species" status in the present rapidly changing fiscal and academic environment. The organizing committee desired to honor the energy and contributions of Dr. D'Angio by establishing an award in his name to reward those we knew he would most like to reward, the young investigators who will be the future leaders in pediatric oncology.